381 related articles for article (PubMed ID: 36925917)
1. Progression in immunotherapy for advanced prostate cancer.
Liang H; Liu Y; Guo J; Dou M; Zhang X; Hu L; Chen J
Front Oncol; 2023; 13():1126752. PubMed ID: 36925917
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.
Bansal D; Reimers MA; Knoche EM; Pachynski RK
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477569
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Laccetti AL; Subudhi SK
Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
[TBL] [Abstract][Full Text] [Related]
4. Immunodiagnostics and Immunotherapy Possibilities for Prostate Cancer.
Schatten H
Adv Exp Med Biol; 2018; 1096():185-194. PubMed ID: 30324354
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.
Reimers MA; Slane KE; Pachynski RK
Curr Urol Rep; 2019 Sep; 20(10):64. PubMed ID: 31482315
[TBL] [Abstract][Full Text] [Related]
9. Immunobiology and immunotherapy in genitourinary malignancies.
Tsiatas M; Grivas P
Ann Transl Med; 2016 Jul; 4(14):270. PubMed ID: 27563657
[TBL] [Abstract][Full Text] [Related]
10. Advances in bio-immunotherapy for castration-resistant prostate cancer.
Lin C; Chen Y; Shi L; Lin H; Xia H; Yin W
J Cancer Res Clin Oncol; 2023 Nov; 149(14):13451-13458. PubMed ID: 37460807
[TBL] [Abstract][Full Text] [Related]
11. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
12. Development of Cancer Immunotherapies.
DeLucia DC; Lee JK
Cancer Treat Res; 2022; 183():1-48. PubMed ID: 35551655
[TBL] [Abstract][Full Text] [Related]
13. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
14. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
15. [New progress of castration-resistant prostate cancer immunotherapy].
Liu JP; Wang H
Zhonghua Wai Ke Za Zhi; 2016 Oct; 54(10):787-791. PubMed ID: 27686644
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp RT; McNeel DG
Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
[TBL] [Abstract][Full Text] [Related]
17. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.
McNeel DG; Bander NH; Beer TM; Drake CG; Fong L; Harrelson S; Kantoff PW; Madan RA; Oh WK; Peace DJ; Petrylak DP; Porterfield H; Sartor O; Shore ND; Slovin SF; Stein MN; Vieweg J; Gulley JL
J Immunother Cancer; 2016; 4():92. PubMed ID: 28031820
[TBL] [Abstract][Full Text] [Related]
18. Prospects of immunotherapy for the treatment of prostate carcinoma--a review.
Hillman GG; Triest JA; Cher ML; Kocheril SV; Talati BR
Cancer Detect Prev; 1999; 23(4):333-42. PubMed ID: 10403905
[TBL] [Abstract][Full Text] [Related]
19. Revisiting Immunotherapy: A Focus on Prostate Cancer.
Cha HR; Lee JH; Ponnazhagan S
Cancer Res; 2020 Apr; 80(8):1615-1623. PubMed ID: 32066566
[TBL] [Abstract][Full Text] [Related]
20. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
